SCHEMBL2931454

SCHEMBL2931454

CC(=O)C(C)Oc1cccc(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.56
KMT2A Q03164 2/20 0.53
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
FOLH1 Q04609 1/20 0.49
NR4A2 P43354 2/20 0.49
KMO O15229 1/20 0.47
NR1H4 Q96RI1 2/20 0.47
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
RAB9A P51151 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30184304 0.84 RXRA (0.68) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL592781 0.84 RXRA (0.68) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL2878702 0.84 AKR1C3 (0.61) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL7944868 0.83 SMN1; SMN2 (0.51) KMT2ALMNACES2CES1NPC1
SCHEMBL8517905 0.82 AKR1C3 (0.59) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL19725364 0.81 GAA (0.58) KMT2AGAAPOLBCYP2C9
SCHEMBL9900712 0.81 GAA (0.58) KMT2AGAAPOLBCYP2C9
SCHEMBL9005586 0.81 AKR1C3 (0.58) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL28317301 0.81 AKR1C3 (0.58) AKR1C3KMT2ARXRARXRBFOLH1
SCHEMBL15329830 0.79 MAOB (0.54) KMT2AGAANPC1CYP2C9RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
CN-101522618-A 3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN disclosed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 AKR1C3 768/4885KMT2A 1003/4885RXRA 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.